Completed × Sarcoma × Gastrointestinal × Clear all
NCT06171945 2025-10-27

AYAConnect

UNC Lineberger Comprehensive Cancer Center

Phase NA Completed
63 enrolled
NCT05131815 2025-02-26

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

Cedars-Sinai Medical Center

Phase NA Completed
8 enrolled
NCT03213665 2025-01-27

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
20 enrolled 12 charts
NCT03213678 2025-01-27

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
18 enrolled 12 charts
NCT03220035 2025-01-27

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
4 enrolled 12 charts
NCT03154190 2025-01-24

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Stanford University

Phase NA Completed
128 enrolled 24 charts
NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Cyteir Therapeutics, Inc.

Phase 1/2 Completed
169 enrolled
NCT03233204 2024-12-11

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
6 enrolled 12 charts
NCT03526250 2024-11-01

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 11 charts
NCT03752398 2024-07-05

DUET-3

Xencor, Inc.

Phase 1 Completed
198 enrolled
NCT04604158 2024-05-21

Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients

Cedars-Sinai Medical Center

Phase NA Completed
38 enrolled
NCT00020267 2024-03-04

Vaccine Therapy in Treating Patients With Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT03454451 2023-12-21

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Corvus Pharmaceuticals, Inc.

Phase 1 Completed
117 enrolled
NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Deciphera Pharmaceuticals, LLC

Phase 1 Completed
282 enrolled
NCT01624220 2023-12-05

A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy

M.D. Anderson Cancer Center

Phase NA Completed
41 enrolled
NCT02890758 2023-02-21

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Case Comprehensive Cancer Center

Phase 1 Completed
14 enrolled
NCT04430842 2023-01-18

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

Phase 1 Completed
15 enrolled
NCT00007813 2020-02-17

Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
21 enrolled
NCT00477919 2019-05-15

E-MOSAIC Electronic Tool to Monitor Symptoms

Swiss Cancer Institute

Completed
264 enrolled